The results indicate that CTCs and cCSCs were independent predictors of cancer progression and OS and that patients with a high baseline CD8+ proportion had longer OS, while patients with a lower CD4: CD8 ratio had longer PFS. This evidence concerns the gene CD4 and cancer.